Heroin addicts are known to have elevated rates of infection. This proposal is directed at determining the effect of opiates on immunocompetence. On the in vitro level, studies will examine whether opiates and opioid peptides can alter T cell responses. Opiates such as morphine, antagonists such as naloxone, and opioid peptides, such as beta-endorphin, methionine-enkephalin, and leucine-enkephalin, will be tested for their effect on T cell proliferation in cultures of rat splenocytes and thymocytes. [3H)Thymidine incorporation into DNA in the presence of T cell mitogens will be used as a measure of proliferation. Calcium influx is one of the earliest events associated with mitogen- stimulated T cell activation. Opioids will also be tested for their effect on basal and mitogen-stimulated 45 Ca 2+ uptake into lymphocytes. The binding and internalization of [125I] beta-endorphin into lymphocytes will be characterized. The ability of opiates and opioid peptides to block [125] beta endorphin binding site on lymphocytes will be compared to the beta-endorphin binding site in the central nervous system. Hemolytic plaque assays will be used to determine if opioids can alter antibody synthesis. Natural killer cytotoxicity as measured by a standard 51 Cr release assay, will determine if opioids can alter the cell-mediated killing target cells. On the in vivo level, these assays will be used to detect alterations in the immunce cell responses of morphine-dependent rats, compared with placebo-treated controls. These studies will results in a better understanding of how opiates modulate immunocompetence and may help explain why heroin addicts are very susceptible to viral infection.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA004355-02
Application #
3209893
Study Section
Sociobehavioral Subcommittee (DAAR)
Project Start
1989-08-01
Project End
1992-07-31
Budget Start
1990-08-01
Budget End
1991-07-31
Support Year
2
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Rochester
Department
Type
Schools of Dentistry
DUNS #
208469486
City
Rochester
State
NY
Country
United States
Zip Code
14627
Parkhill, Amy L; Bidlack, Jean M (2006) Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. Int Immunopharmacol 6:1013-9
Bidlack, Jean M; Khimich, Maxim; Parkhill, Amy L et al. (2006) Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol 1:260-9
Gekker, Genya; Hu, Shuxian; Wentland, Mark P et al. (2004) Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther 309:600-6
Peterson, P K; Gekker, G; Lokensgard, J R et al. (2001) Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes. Biochem Pharmacol 61:1145-51
Bidlack, J M; Abraham, M K (2001) Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression. Adv Exp Med Biol 493:103-10
Martin-Kleiner, I; Bidlack, J M (2001) Chronic opioid treatment of the mouse thymoma cell lines R1.G1 and R1EGO leads to down-regulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity. Int Immunopharmacol 1:13-20
Bidlack, J M (2000) Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol 7:719-23
Ignatowski, T A; Bidlack, J M (1999) Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J Pharmacol Exp Ther 290:863-70
Martin-Kleiner, I; Bidlack, J M (1999) The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line. Int J Immunopharmacol 21:133-40
Ignatowski, T A; Bidlack, J M (1998) Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther 284:298-306

Showing the most recent 10 out of 24 publications